Welcome to CRWENewswire, Shares to Watch. I'm Shalika Jayasekera. Ventrus BioSciences Integrated - image VTUS - reported that it has accomplished its acquisition of all rights and title to VEN 309 - iferanserin ointment for the therapy of symptomatic hemorrhoids - from the licensor, Sam Amer & Firm. Primarily based on a report by the Nationwide Institute of Diabetes and Digestive Kidney Illnesses, the corporate estimates that symptomatic hemorrhoids presently have an effect on roughly 12.5 million adults. Ventrus is a improvement stage specialty pharmaceutical firm centered on the event of late-stage prescribed drugs for gastrointestinal issues. Thanks for becoming a member of me and have an incredible day! For CRWE Newswire, Shares to look at, I’m Shalika Jayasekera
Home Unlabelled Ventrus Biosciences, Inc. (VTUS) Acquisition of Title to Hemorrhoids Product - CRWENewswire
Ventrus Biosciences, Inc. (VTUS) Acquisition of Title to Hemorrhoids Product - CRWENewswire
By . At October 12, 2018 0
Ventrus Biosciences, Inc. (VTUS) Acquisition of Title to Hemorrhoids Product - CRWENewswire
Welcome to CRWENewswire, Shares to Watch. I'm Shalika Jayasekera. Ventrus BioSciences Integrated - image VTUS - reported that it has accomplished its acquisition of all rights and title to VEN 309 - iferanserin ointment for the therapy of symptomatic hemorrhoids - from the licensor, Sam Amer & Firm. Primarily based on a report by the Nationwide Institute of Diabetes and Digestive Kidney Illnesses, the corporate estimates that symptomatic hemorrhoids presently have an effect on roughly 12.5 million adults. Ventrus is a improvement stage specialty pharmaceutical firm centered on the event of late-stage prescribed drugs for gastrointestinal issues. Thanks for becoming a member of me and have an incredible day! For CRWE Newswire, Shares to look at, I’m Shalika Jayasekera
Welcome to CRWENewswire, Shares to Watch. I'm Shalika Jayasekera. Ventrus BioSciences Integrated - image VTUS - reported that it has accomplished its acquisition of all rights and title to VEN 309 - iferanserin ointment for the therapy of symptomatic hemorrhoids - from the licensor, Sam Amer & Firm. Primarily based on a report by the Nationwide Institute of Diabetes and Digestive Kidney Illnesses, the corporate estimates that symptomatic hemorrhoids presently have an effect on roughly 12.5 million adults. Ventrus is a improvement stage specialty pharmaceutical firm centered on the event of late-stage prescribed drugs for gastrointestinal issues. Thanks for becoming a member of me and have an incredible day! For CRWE Newswire, Shares to look at, I’m Shalika Jayasekera
